Emina E Torlakovic

Emina E Torlakovic

UNVERIFIED PROFILE

Are you Emina E Torlakovic?   Register this Author

Register author
Emina E Torlakovic

Emina E Torlakovic

Publications by authors named "Emina E Torlakovic"

Are you Emina E Torlakovic?   Register this Author

32Publications

797Reads

14Profile Views

Uneven Staining in Automated Immunohistochemistry: Cold and Hot Zones and Implications for Immunohistochemical Analysis of Biopsy Specimens.

Appl Immunohistochem Mol Morphol 2018 May/Jun;26(5):299-304

Department of Pathology and Laboratory Medicine, Royal University Hospital, College of Medicine, University of Saskatchewan and Saskatchewan Health Authority, Saskatoon, Saskatchewan, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAI.0000000000000656DOI Listing
June 2019

Diagnostic Accuracy in Fit-for-Purpose PD-L1 Testing.

Appl Immunohistochem Mol Morphol 2019 04;27(4):251-257

Canadian Immunohistochemistry Quality Control.

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00129039-900000000-9873
Publisher Site
http://dx.doi.org/10.1097/PAI.0000000000000734DOI Listing
April 2019

An Audit of Failed Immunohistochemical Slides in a Clinical Laboratory: The Role of On-Slide Controls.

Appl Immunohistochem Mol Morphol 2017 May/Jun;25(5):308-312

*Department of Pathology, Laboratory Medicine Program, University Health Network †Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada ‡Keck School of Medicine, University of Southern California, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAI.0000000000000305DOI Listing
November 2017

Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine: Part 4: Tissue Tools for Quality Assurance in Immunohistochemistry.

Appl Immunohistochem Mol Morphol 2017 04;25(4):227-230

*Department of Laboratory Medicine and Pathobiology, University of Toronto Departments of †Pathology §§§§Laboratory Hematology, University Health Network, Toronto, ON §§Vancouver General Hospital, University of British Columbia, Vancouver, BC ###Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB ∥∥∥∥Canadian Immunohistochemistry Quality Control (CIQC)/Canadian Association of Pathologists National Standards Committee for High Complexity Testing/Immunohistochemistry, Canada ‡Poundbury Cancer Institute §Dorset County Hospital NHS Foundation Trust ∥Cancer Diagnostic Quality Assurance Services (CADQAScic), Dorchester ¶¶Department of Surgery & Cancer, Division of Cancer, Imperial College London ***UK National External Quality Assessment Scheme (UK NEQAS), University College London, London, UK ∥∥International Quality Network for Pathology (IQN Path), Luxembourg City, Luxembourg ¶School of Medicine, Institute of Pathology, Charité-University Hospital Berlin, Berlin, Germany #Griffith University, Gold Coast ††Genomics For Life, Brisbane, Qld **RCPA Quality Assurance Program, Sydney, NSW, Australia ‡‡Phenopath, Seattle, WA ##Brigham and Women's Hospital, Harvard Medical School, Boston, MA ****Keck School of Medicine, University of Southern California, Los Angeles, CA †††Center of Predictive Molecular Medicine ‡‡‡Center for Excellence on Ageing and Translational Medicine, University of Chieti-Pescara, Chieti, Italy §§§Department of Pathology, Radboud University Medical Centre, Nijmegen, The Netherlands ∥∥∥Institute of Pathology, Aalborg University Hospital and Department of Clinical Medicine, Aalborg University ¶¶¶Nordic Immunohistochemistry Quality Control (NordiQC), Aalborg, Denmark ††††Department of Pathology, Beijing Friendship Hospital, Capital Medical University, Beijing ‡‡‡‡Chinese Committee for Pathologists-Immunohistochemistry Quality Control, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAI.0000000000000469DOI Listing
April 2017

Characterization of the Antibody Response after Cervical Spinal Cord Injury.

J Neurotrauma 2017 03 21;34(6):1209-1226. Epub 2016 Dec 21.

1 Division of Genetics and Development, Toronto Western Research Institute and University of Toronto Spinal Program, Krembil Neuroscience Center, University Health Network , Toronto, Ontario, Canada .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/neu.2016.4498DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5359645PMC
March 2017

Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine. Part 3: Technical Validation of Immunohistochemistry (IHC) Assays in Clinical IHC Laboratories.

Appl Immunohistochem Mol Morphol 2017 03;25(3):151-159

*Department of Laboratory Medicine and Pathobiology, University of Toronto Departments of †Laboratory Hematology §Pathology, University Health Network, Toronto, ON ∥∥Vancouver General Hospital, University of British Columbia, Vancouver, BC ¶¶¶Department of Pathology and Laboratory Medicine, Cumming School of Medicine University of Calgary, and Calgary Laboratory Services, Calgary, AB, Canada ‡Canadian Immunohistochemistry Quality Control (CIQC), Vancouver, BC, Canada/Canadian Association of Pathologists National Standards Committee for High Complexity Testing/Immunohistochemistry ∥Poundbury Cancer Institute ¶Dorset County Hospital NHS Foundation Trust, Dorchester, UK #Cancer Diagnostic Quality Assurance Services (CADQAScic), Dorchester ***UK National External Quality Assessment Scheme (UK NEQAS), University College London, London, UK **School of Medicine, Institute of Pathology, Charité-University Hospital, Berlin, Berlin, Germany ††Griffith University, Gold Coast ‡‡RCPA Quality Assurance Program, Sydney §§Genomics For Life, Brisbane, Australia ¶¶International Quality Network for Pathology (IQN Path), Luxembourg City, Luxembourg ##Brigham and Women's Hospital, Harvard Medical School, Boston, MA †††Center of Predictive Molecular Medicine, Center for Excellence on Ageing and Translational Medicine, University of Chieti-Pescara, Chieti, Italy ‡‡‡Department of Pathology, Radboud University Medical Centre, Nijmegen, The Netherlands §§§Institute of Pathology, and Department of Clinical Medicine, Aalborg University, Aalborg University Hospital ∥∥∥Nordic Immunohistochemistry Quality Control (NordiQC), Aalborg, Denmark ###Department of Pathology, Beijing Friendship Hospital, Capital Medical University, Beijing ****Chinese Committee for Pathologists-Immunohistochemistry Quality Control, China ††††Keck School of Medicine, University of Southern California, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAI.0000000000000470DOI Listing
March 2017

Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine - Part 2: Immunohistochemistry Test Performance Characteristics.

Appl Immunohistochem Mol Morphol 2017 02;25(2):79-85

*Department of Laboratory Medicine and Pathobiology, University of Toronto, Vancouver, BC, CanadaDepartment of †Laboratory Hematology§Pathology, University Health Network, Toronto, ON, Canada‡Canadian Immunohistochemistry Quality Control (CIQC)/Canadian Association of Pathologists National Standards Committee for High Complexit Testing/Immunohistochemistry∥Poundbury Cancer Institute¶Dorset County Hospital NHS Foundation Trust#Cancer Diagnostic Quality Assurance Services (CADQAScic), Dorchester, UK***UK National External Quality Assessment Scheme (UK NEQAS), University College London, London, UK**"Rudolf-Virchow-Haus", Institute of Pathology, Charité-University Hospital Berlin, Berlin, Germany††School of Medicine, Griffith University, Gold Coast‡‡Genomics For Life, Brisbane, QLD§§RCPA Quality Assurance Program, Sydney, NSW, Australia∥∥Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada¶¶International Quality Network for Pathology (IQN Path), Luxembourg City, Luxembourg, and Division of Cancer, Department of Surgery & Cancer, Imperial College London, UK##Brigham and Women's Hospital, Harvard Medical School, Boston, MA†††Center of Predictive Molecular Medicine, Center for Excellence on Ageing and Translational Medicine, University of Chieti-Pescara, Chieti, Italy‡‡‡Department of Pathology, Radboud University Medical Centre, Nijmegen, The Netherlands§§§Institute of Pathology, Aalborg University Hospital and Department of Clinical Medicine, Aalborg University, Denmark∥∥∥Nordic Immunohistochemistry Quality Control (NordiQC), Aalborg, Denmark¶¶¶Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary and Calgary Laboratory Services, Calgary, AB###Department of Pathology, Beijing Friendship Hospital, Capital Medical University****CCP-IHCQC, Chinese Committee for Pathologists-Immunohistochemistry Quality Control, Beijing, China††††Keck School of Medicine, University of Southern California, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAI.0000000000000444DOI Listing
February 2017

Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine: Part 1: Fit-for-Purpose Approach to Classification of Clinical Immunohistochemistry Biomarkers.

Appl Immunohistochem Mol Morphol 2017 01;25(1):4-11

*Department of Laboratory Medicine and Pathobiology, University of Toronto †Department of Pathology, University Health Network ††††Department of Laboratory Hematology, University Health Network, Toronto, ON ‡‡Vancouver General Hospital, University of British Columbia, Vancouver, BC ∥∥∥Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada ‡Poundbury Cancer Institute §Dorset County Hospital NHS Foundation Trust ∥Cancer Diagnostic Quality Assurance Services (CADQAScic), Dorchester ∥∥Division of Cancer, Department of Surgery & Cancer, Imperial College, London, UK ##UK National External Quality Assessment Scheme (UK NEQAS), University College London, London, UK ¶School of Medicine, Institute of Pathology, Charité-University Hospital Berlin, Berlin, Germany #Griffith University, Gold Coast **RCPA Quality Assurance Program, Sydney ††Genomics For Life, Brisbane, Australia §§International Quality Network for Pathology (IQN Path), Luxembourg City, Luxembourg ¶¶Brigham and Women's Hospital, Harvard Medical School, Boston, MA ***Center of Predictive Molecular Medicine, Center for Excellence on Ageing and Translational Medicine, University of Chieti-Pescara, Chieti, Italy †††Department of Pathology, Radboud University Medical Centre, Nijmegen, The Netherlands ‡‡‡Institute of Pathology, Aalborg University Hospital and Department of Clinical Medicine, Aalborg University §§§Nordic Immunohistochemistry Quality Control (NordiQC), Aalborg, Denmark ¶¶¶Keck School of Medicine, University of Southern California, Los Angeles, CA ###Department of Pathology, Beijing Friendship Hospital, Capital Medical University, Beijing, China ****Chinese Committee for Pathologists-Immunohistochemistry Quality Control ‡‡‡‡Canadian Immunohistochemistry Quality Control (CIQC)/Canadian Association of Pathologists National Standards Committee for High Complexity Testing/Immunohistochemistry, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAI.0000000000000451DOI Listing
January 2017

Developing ALK Immunohistochemistry and In Situ Hybridization Proficiency Testing for Non-Small Cell Lung Cancer in Canada: Canadian Immunohistochemistry Quality Control Challenges and Successes.

Appl Immunohistochem Mol Morphol 2015 Nov-Dec;23(10):677-81

*Laboratory Medicine Program, University Health Network, University of Toronto, Toronto ‡Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON †Canadian Immunohistochemistry Quality Control §Department of Pathology, Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAI.0000000000000267DOI Listing
August 2016

The role of diagnostic tissue in research.

Pathobiology 2014 16;81(5-6):298-303. Epub 2015 Mar 16.

Department of Pathology, University Health Network, Toronto, Ont., Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000362648DOI Listing
November 2015

Modeling complexity in pathologist workload measurement: the Automatable Activity-Based Approach to Complexity Unit Scoring (AABACUS).

Mod Pathol 2015 Mar 12;28(3):324-39. Epub 2014 Sep 12.

1] Department of Pathology, Laboratory Medicine Program, University Health Network, Toronto, ON, Canada [2] Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/modpathol2014123
Publisher Site
http://dx.doi.org/10.1038/modpathol.2014.123DOI Listing
March 2015

Enteropathy-associated intestinal T-cell lymphoma in cavitating mesenteric lymph node syndrome: fine-needle aspiration contributes to the diagnosis.

Diagn Cytopathol 2015 Feb 8;43(2):125-30. Epub 2014 Mar 8.

Laboratory Medicine Program, University Health Network, Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/dc.23144DOI Listing
February 2015

Standardization of positive controls in diagnostic immunohistochemistry: recommendations from the International Ad Hoc Expert Committee.

Appl Immunohistochem Mol Morphol 2015 Jan;23(1):1-18

*Department of Laboratory Hematology, Toronto General Hospital, University Health Network, University of Toronto, Toronto, ON **Vancouver Costal Health ††Vancouver General Hospital/University of British Columbia, Vancouver, BC ##Department of Pathology, University of Calgary, Calgary, AB, Canada †Canadian Immunohistochemistry Quality Control (CIQC), Vancouver, BC, Canada ‡Institute of Pathology, Aalborg University Hospital, Denmark §Nordic Immunohistochemistry Quality Control (NordiQC), Aalborg, Denmark ∥Griffith University School of Medicine, Gold Coast Campus ¶Australian Institute for Bioengineering and Nano-Technology, University of Queensland, Qld, Australia #Convenor Immunohistochemistry, Anatomical Pathology Program, RCPA QAP Pty Ltd., Sydney, Australia ‡‡Beth Israel Deaconess Medical Center §§Brigham and Women's Hospital, Harvard medical School, Boston, MA ∥∥UK National External Quality Assessment Scheme (UK NEQAS), University College London, London, UK ¶¶University of Washington, Seattle, WA ***Department of Pathology, Beijing Friendship Hospital, Capital Medical University, Beijing, China †††Chinese Committee for Pathology-Immunohistochemistry Quality Control (CCP-IHCQC) ‡‡‡Keck School of Medicine, University of Southern California, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/appliedimmunohist/2015/01000/St
Web Search
http://dx.doi.org/10.1097/PAI.0000000000000163DOI Listing
January 2015

Sessile serrated polyps at screening colonoscopy: have they been under diagnosed?

Am J Gastroenterol 2014 Nov 8;109(11):1698-704. Epub 2014 Jul 8.

1] Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada [2] Cancer Care Ontario, Toronto, Ontario, Canada [3] Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada [4] Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada [5] Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ajg.2014.78DOI Listing
November 2014

HER2/neu testing in gastric cancer by immunohistochemistry: assessment of interlaboratory variation.

Arch Pathol Lab Med 2014 Nov;138(11):1495-502

From the Division of Anatomic Pathology, Department of Pathology and Laboratory Medicine, Vancouver General Hospital and the University of British Columbia, Vancouver, Canada (Drs Sheffield, Gilks, and Schaeffer and Mr Garratt); the Canadian Immunohistochemistry Quality Control Program, Vancouver (Mr Garratt and Drs Torlakovic and Gilks); the Department of Pathology and Laboratory Medicine, British Columbia Cancer Agency and the University of British Columbia, Vancouver (Dr Li-Chang and Mr Kalloger); and the Department of Laboratory Hematology, University Health Network, University of Toronto, Toronto, Ontario, Canada (Dr Torlakovic).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5858/arpa.2013-0604-OADOI Listing
November 2014

Langerhans cell histiocytosis in acute leukemias of ambiguous or myeloid lineage in adult patients: support for a possible clonal relationship.

Mod Pathol 2014 May 1;27(5):651-6. Epub 2013 Nov 1.

Special Hematology Laboratory, Division of Hematopathology, University of Minnesota Medical Center, Fairview, Minneapolis, MN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/modpathol.2013.181DOI Listing
May 2014

Standardization of negative controls in diagnostic immunohistochemistry: recommendations from the international ad hoc expert panel.

Appl Immunohistochem Mol Morphol 2014 Apr;22(4):241-52

*Laboratory Medicine Program, University Health Network/University of Toronto, Toronto, ON #Department of Pathology, Lions Gate Hospital **Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada †Canadian Immunohistochemistry Quality Control ‡CAP-ACP National Standards Committee for High Complexity Testing/Immunohistochemistry §Griffith University School of Medicine, Gold Coast ¶Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Qld, Australia ∥Convenor Immunohistochemistry, Anatomical Pathology Program, RCPA QAP Pty Ltd. ††University College London, UK NEQAS ICC&ISH, London, UK ‡‡ProPath, Dallas, TX §§Institute of Pathology, Aalborg University Hospital, Aalborg, Denmark ∥∥Nordic Immunohistochemical Quality Control (NordiQC) ¶¶Department of Pathology, University of Washington, Seattle, WA ##Department of Pathology, Keck School of medicine, University of Southern California, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/PAI.0000000000000069DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4206554PMC
April 2014

Diagnostic utility of androgen receptor expression in discriminating poorly differentiated urothelial and prostate carcinoma.

J Clin Pathol 2013 Sep 17;66(9):779-86. Epub 2013 Jun 17.

Department of Pathology and Laboratory Medicine, University Health Network, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jclinpath-2013-201586DOI Listing
September 2013

Fli-1 expression in malignant melanoma.

Histol Histopathol 2008 11;23(11):1309-14

Department of Pathology, Royal University Hospital, Saskatoon, SK, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14670/HH-23.1309DOI Listing
November 2008

CD10 protein expression in tumor and stromal cells of malignant melanoma is associated with tumor progression.

Mod Pathol 2004 Oct;17(10):1251-8

Department of Pathology, University Hospital Sarajevo, Bosnia and Herzegovina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/modpathol.3800174DOI Listing
October 2004